United Therapeutics (NASDAQ:UTHR) CEO Sells $5,205,145.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $547.91, for a total value of $5,205,145.00. Following the sale, the chief executive officer owned 40,513 shares of the company’s stock, valued at $22,197,477.83. This represents a 19.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

United Therapeutics Price Performance

Shares of NASDAQ:UTHR traded down $4.66 during trading on Tuesday, hitting $539.96. 478,809 shares of the company’s stock were exchanged, compared to its average volume of 468,752. United Therapeutics Corporation has a 52-week low of $272.12 and a 52-week high of $609.35. The business’s 50-day simple moving average is $566.86 and its 200 day simple moving average is $516.87. The company has a market cap of $22.92 billion, a price-to-earnings ratio of 19.93, a PEG ratio of 1.81 and a beta of 0.60.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The firm had revenue of $781.50 million during the quarter, compared to the consensus estimate of $797.40 million. During the same period in the previous year, the firm earned $6.63 EPS. The business’s revenue was down 1.6% compared to the same quarter last year. On average, sell-side analysts anticipate that United Therapeutics Corporation will post 26.92 EPS for the current fiscal year.

Hedge Funds Weigh In On United Therapeutics

A number of large investors have recently bought and sold shares of UTHR. Avoro Capital Advisors LLC boosted its holdings in United Therapeutics by 17.3% during the 4th quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock valued at $1,269,803,000 after acquiring an additional 383,838 shares during the period. Wellington Management Group LLP boosted its holdings in United Therapeutics by 74.5% during the 4th quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock valued at $1,189,617,000 after acquiring an additional 1,042,711 shares during the period. AQR Capital Management LLC boosted its holdings in United Therapeutics by 29.9% during the 4th quarter. AQR Capital Management LLC now owns 1,281,699 shares of the biotechnology company’s stock valued at $624,508,000 after acquiring an additional 295,221 shares during the period. Janus Henderson Group PLC boosted its holdings in United Therapeutics by 8.9% during the 1st quarter. Janus Henderson Group PLC now owns 866,930 shares of the biotechnology company’s stock valued at $514,016,000 after acquiring an additional 70,829 shares during the period. Finally, Darwin Global Management Ltd. purchased a new position in United Therapeutics during the 3rd quarter valued at $317,617,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have issued reports on UTHR. Raymond James Financial began coverage on United Therapeutics in a research note on Friday, April 10th. They issued an “outperform” rating and a $700.00 price objective on the stock. Wells Fargo & Company raised United Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $575.00 to $735.00 in a research note on Thursday, May 7th. Royal Bank Of Canada reduced their price objective on United Therapeutics from $707.00 to $701.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. UBS Group lifted their price objective on United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a research note on Thursday, March 5th. Finally, Jefferies Financial Group reaffirmed a “buy” rating on shares of United Therapeutics in a research note on Monday, March 2nd. Eleven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $619.42.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.